Filing Flows › Protagonist Therapeutics (PTGX) › Recalls, complaints & regulation
Protagonist Therapeutics (PTGX): clinical trials
Protagonist Therapeutics (PTGX) beyond its filings: 2 active clinical trials.
Protagonist Therapeutics' latest quarter
Protagonist Therapeutics, Q3 2026: revenue $274M (58× year over year), operating margin 79.6%, net earnings $220M, operating cash flow −$23.2M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Protagonist Therapeutics have?
2 active studies on ClinicalTrials.gov, 2 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.